FindTrial
Sign In

A pilot study for optimizing meropenem administration in the intensive care unit – short six times vs. prolonged three times courses daily

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-520030-30-00
Acronym
Mer-6
Enrollment
50
Registered
2025-01-23
Start date
2025-01-23
Completion date
Unknown
Last updated
2025-01-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Serious infection requiring broad-spectrum antibiotic

Brief summary

Proportion of patients who achieve adequate meropenem concentration (>2 mg/l) > 50% of the time per day (50% T>MIC) when dosing with more frequent and shorter infusions after 1, 2 and 3 days

Detailed description

Proportion of patients who achieve adequate meropenem concentration (>2 mg/l) > 100% of the time per day (50% T>MIC) when dosing with more frequent and shorter infusions after 1, 2 and 3 days, Lenght of stay in the intensive care unit., Mortality 30 days after admission to the intensive care unit., Serious adverse events

Interventions

DRUGMEROPENEM

Sponsors

Oslo University Hospital HF
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Proportion of patients who achieve adequate meropenem concentration (>2 mg/l) > 50% of the time per day (50% T>MIC) when dosing with more frequent and shorter infusions after 1, 2 and 3 days—

Secondary

MeasureTime frame
Proportion of patients who achieve adequate meropenem concentration (>2 mg/l) > 100% of the time per day (50% T>MIC) when dosing with more frequent and shorter infusions after 1, 2 and 3 days, Lenght of stay in the intensive care unit., Mortality 30 days after admission to the intensive care unit., Serious adverse events—

Countries

Norway

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026